Autolus Therapeutics (AUTL) said Tuesday that the National Institute for Health and Care Excellence has recommended leukemia drug Aucatzyl for use in the National Health Service in England and Wales to treat adult patients.
The company said it plans to launch the drug in England and Wales "imminently."
Autolus also plans to pursue patient access to the drug through the Scottish Medical Consortium, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments